Hemostatic Powder for Non‐Malignant Upper Gastrointestinal Bleeding: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Journal of Gastroenterology and Hepatology · 2026-03 · 41 (3) · 854-862
DOI: 10.1111/jgh.70249 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 23.01.2026. Verfasst von Paula Santo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Texas Tech University Health Sciences Center, Lubbock, Texas, USA. Hauptthemen laut MEDLINE: Gastrointestinal Hemorrhage, Randomized Controlled Trials as Topic, Hemostatics, Hemostasis, Endoscopic. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background and Aim The effectiveness of standard endoscopic treatment (SET) for non‐variceal upper gastrointestinal bleeding (NVUGIB) may vary, particularly depending on the bleeding site, lesion size, and etiology. Recent studies suggest that hemostatic powder (HP) may effectively control bleeding secondary to malignant upper gastrointestinal lesions, but its efficacy in benign etiology for NVUGIB remains uncertain. This systematic review and meta‐analysis aimed to compare the effectiveness of HP versus SET as first‐line therapy for patients with non‐malignant causes of NVUGIB.
Methods
We systematically searched PubMed, Embase, and Cochrane Library databases for randomized controlled trials (RCTs) from inception to January 2025. We used risk ratios (RR) for binary outcomes and mean differences (MD) for continuous outcomes with their corresponding 95% confidence intervals (CIs).
Results
We included 5 RCTs (708 patients). Compared to SET, HP was associated with marginally lower risk of further bleeding during esophagogastroduodenoscopy (EGD) (RR 1.04; 95% CI [1.001, 1.084]; p = 0.04) and similar rebleeding rate within 1, 3, 7, 15, and 30 days. The need for a second endoscopic treatment and the mean procedure time were similar between the groups. Subgroup analyses showed that HP has a lower risk of further bleeding during EGD only when analyzing Forrest IIa lesions, but not in active bleeding.
Conclusions
In patients with non‐malignant NVUGIB, HP demonstrated lower risk of further bleeding during EGD in cases with non‐bleeding visible vessels. There was no statistically significant difference in further bleeding during EGD for active bleeding, nor in rebleeding risk at 1, 3, 7, 15, or 30 days.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Department, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
- Division of Gastroenterology, Internal Medicine Department, FEEVALE University, Novo Hamburgo, Brazil.
- Internal Medicine Department, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
- Internal Medicine Department, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Endoscopy Unit, University of Sao Paulo - Institute of Cancer of Sao Paulo State, São Paulo, Brazil.
ORCID-Profile: Paula Santo
Zitieren
APA
Santo, P., Meine, G. C., Prado, R. M. G., Pessorrusso, F., Bilal, M., & Maluf-Filho, F. (2026). Hemostatic Powder for Non‐Malignant Upper Gastrointestinal Bleeding: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Journal of Gastroenterology and Hepatology, 41(3), 854-862. https://doi.org/10.1111/jgh.70249
Vancouver
Santo P, Meine GC, Prado RMG, Pessorrusso F, Bilal M, Maluf-Filho F. Hemostatic Powder for Non‐Malignant Upper Gastrointestinal Bleeding: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Journal of Gastroenterology and Hepatology. 2026;41(3):854-862. doi:10.1111/jgh.70249
BibTeX
@article{Santo2026,
author = {Santo, Paula and Meine, Gilmara Coelho and Prado, Renan Martins Gomes and Pessorrusso, Fernanda and Bilal, Mohammad and Maluf-Filho, Fauze},
title = {Hemostatic Powder for Non‐Malignant Upper Gastrointestinal Bleeding: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
volume = {41},
number = {3},
pages = {854--862},
doi = {10.1111/jgh.70249}
}
EUVIMED